parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	genetic association 0.28 (overall 0.17)	0.28
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in renal collecting duct principal cells	0.75
chemistry Open Targets	reachable by antibody	0.36
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	9 Parkinson's papers of 26	0.70
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 2121

LRRC37A2 in dopamine neurons, braak+0.11 (p 0.784) → +0.44 (p 0.234)receipt 2130
LRRC37A2 in astrocytes, braak-0.05 (p 0.891) → +0.19 (p 0.623)receipt 2129

receipt 2130: LRRC37A2 in dopamine neurons, braak

power: full sample +0.30 (p 0.225, n 18), 95% CI -0.19 to +0.67. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.32 (p 0.201, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.37 (p 0.127, n 18). could be the mix.
skeptic: leave-one-out range +0.22 to +0.44, sign flips 0; without severely affected donors +0.30 (p 0.225, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for LRRC37A2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 2129: LRRC37A2 in astrocytes, braak

power: full sample +0.04 (p 0.867, n 18), 95% CI -0.43 to +0.50. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.06 (p 0.800, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.19 (p 0.444, n 18). could be the mix.
skeptic: leave-one-out range -0.07 to +0.18, sign flips 5; without severely affected donors +0.04 (p 0.867, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for LRRC37A2 in astrocytes.

case closed: nothing better to follow up.

loading the receipts